Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-10-18
2005-10-18
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S028400, C514S04400A
Reexamination Certificate
active
06956028
ABSTRACT:
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.
REFERENCES:
patent: 4960759 (1990-10-01), De Luca et al.
patent: 5470838 (1995-11-01), von Borstel et al.
patent: 5736531 (1998-04-01), von Borstel et al.
patent: 5968914 (1999-10-01), von Borstel et al.
patent: 6258795 (2001-07-01), von Borstel et al.
patent: 6316426 (2001-11-01), von Borstel et al.
patent: 2002/0028787 (2002-03-01), Watkins et al.
patent: WO 00/06174 (2000-02-01), None
patent: 00/50043 (2000-08-01), None
The Merck Manual, 1987, pp. 1221-1226.
Chen et al; “Effect of Anti-Human Immunodeficiency Virus Nucleoside Analogs on Mitochondrial DNA and Its Implication for Delayed Toxicity”; Molec. Pharmacol; 39:625-628; (1991).
Keilbaugh et al; “Anti-Human Immunodeficiency Virus Type 1 Therapy and Peripheral Neuropathy: Prevention of 2′,3′-Dideoxycytidine Toxicity in PC12 Cells, a Neuronal Model, by Uridine and Pyruvate”; Molec. Pharmacol. 44:702-706 (1993).
Morais, R., and Guertin, D.,Can. J. Biochem., vol. 60, p. 290-294, 1982 “On the contribution of the mitochondrial genome to the growth of Chinese hamster embryo cells in culture”.
Morias, R., et al.,In Vitro Cellular&Development Biology, vol. 24, No. 7, Jul. 1988, p. 649-658, Development and Characterization of Continuous Avian Cell Lines “Depleted of Mitochondrial DNA”.
Bodnar, Andrea G., et al.,Biochem. J., (1995) 817-822, “Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication”.
Bourgeron, Thomas, et al,The Journal of Biological Chemistry, vol. 268, No. 26, Sep. 15, 1993, pp. 19369-19376, “Fate and expression of the deleted mitochrondrial DNA differ between human heteroplasmic skiri fibroblast and Epstein-Barr virus-transformed lymphocyte cultures”.
Löffler, Monika, et al,Molecular and Cellular Biochemistry, 174:125-192, 1997, “Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides”.
Page, Theodore, et al,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 11601-11606, Oct. 1997, “Developmental disorder associated with increased cellular nucleotidase activity”.
Secades et al, “Methods and Findings in Experimental . . . ,” 17: Supplement B pp. 1-54, (see p. 38, col 2 through p. 39, col. 1, and 40-43) (1995).
Keilbaugh et al (Mol. Pharm. 44:702-706, abstract only (1995).
Dykens et al, J. Neurochem. 63: 584-591, especially see lines 24-28 of abstract; and p. 589, col 1, first para (1994).
Bodnar et al, Biochem J. 305: 817-822, see especially abstract, lines 6-10 (1995).
Kralovansky et al, “Cancer Chemotherapy and Pharmacology,” 32: 243-248, see abstract, lines 4-7 (1993).
Lipp et al, Biology of the Neonate 33: 62-65, see entire abstract (1978).
Sartori et al, Alcohol 3:97-100, see first and last sentences of abstract (1986).
Agnati et al, Acta Phys. Scanda, 126: 525-531, see abstract, lines 5-15 (1986).
Copy of Current Claims 1-50; von Borstel et al; U.S. Appl. No. 09/930,494; filed Aug. 16, 2001; (Attorney Reference 1331-352).
Copy of Current Claims 1-47; Von Borstel; U. S. Appl. No. 09/763,955, filed Feb. 28, 2001; (Attorney Reference 1331-334.
Wardell, T.M., et al; “Changes in the human mitochondrial genome after treatment of malignant disease”;Muat Res.; 9;525(1-2):19-27 (Apr. 2003) (Abstract).
Sign, G., et al; “Mitochondrial DNA damage by anticancer agents”;Pharmal Ther.; 54(2):217-30 (1992) (Abstract).
Brady, H.R., et al; “Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules”;Am.J. Physiol.; vol. 258(5 Pt 2):F1181-7 (May 1990) (Abstract).
Branda, R.F., et al; “Dietary modulation of mitochondrial DNA deletions and copy No. after chemotherapy in rats”;Mutat REs.; 25;501(1-2):29-36 (Apr. 2000) (Abstract).
Solem, L.E., et al; “Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration”;Toxicol Appl Pharmacol.; 129(2):213-22 (Dec. 1994) (Abstract).
Khaidakov, M., et al; “Molecular analysis of mitochondrial DNA mutations from bleomycin-treated rats”;Mut Res.; 20;500(1-2):1-8 (Mar. 2002) (Abstract).
Pritsos, C.A., et al; “A new cellular target for mitomycin C: a case for mitochondrial DNA”;Oncol Res.; 9(6-7):333-7 (1997) (Abstract).
U.S. Appl. No. 60/121,588, Naviaux, filed Feb. 23, 1999.
Krishnan Ganapathy
Nixon & Vanderhye
Wellstat Therapeutics Coporation
Wilson James O.
LandOfFree
Compositions and methods for treatment of mitochondrial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of mitochondrial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of mitochondrial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464586